Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Immunodeficient Patients with Secondary Lung… >

Immunodeficient Patients with Secondary Lung Disease Benefit from Combined Chemotherapy

Published: August 30, 2012.
Released by Medical College of Wisconsin  

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).The findings are published in the Journal of Clinical Immunology.

Common variable immunodeficiency (CVID) is the most common primary immunodeficiency that requires regular treatment with medication, specifically immunoglobulin (antibodies) replacement therapy. With immunoglobulin therapy, deaths from infection in patients with CVID have decreased and deaths due to non-infectious complications have increased. One of the most frequent causes of death now in CVID is a lung disease known as granulomatous-lymphocytic interstitial lung disease (GLILD). In GLILD, white blood cells abnormally accumulate in the lung, which leads to a progressive decline in lung function and, eventually, respiratory failure. The researchers evaluated patients with GLILD to see if rituximab and azathioprine (combination chemotherapy) would improve pulmonary function and/or radiographic abnormalities by killing these white blood cells in the lung.

"The most common medication used for GLILD are corticosteroids but in our hands this type of medication did not clear the disease. Therefore, we designed therapy aimed at killing the specific type of lymphocytes, B cells and T cells, we found in abnormal numbers in the lung biopsies we examined. We reasoned if we killed the lymphocytes in the lung, lung function and radiographic abnormalities would both improve, which is what we found." said John M. Routes, M.D., professor and chief of asthma, allergy and immunology at the Medical College of Wisconsin (MCW), medical director of allergy/clinical immunology at Children's Hospital and researcher at the Research Institute.




The above story is based on materials provided by Medical College of Wisconsin.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Cells 
5/8/12 

Scientists Discover New Type of Cell with a Key Role in Treatment-resistant Asthma
Asthma 
10/1/14 
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Researchers have identified a molecular mechanism that could explain why the common cold can bring on life-threatening asthma attacks. …
Asthma 
7/13/10 
Interferon Might Help Asthma Patients Breathe Easier, UT Southwestern Study Suggests
DALLAS – July 15, 2010 – An immune-system protein already used to treat diseases like multiple sclerosis, hepatitis C …
Asthma 
7/24/13 
A Promising Target to Treat Asthma
An enzyme known for its role in heart disease may well be a promising target to treat asthma. Researchers …
Patients 
10/25/13 
Hope of New Treatment for Severe Asthma Patients
New research from Japan brings hope of a new treatment for asthma patients resistant to corticosteroids. In a study …
Asthma 
9/18/12 
Hope on the Horizon for Asthma Sufferers
A new study that identifies ways to reduce the factors that lead to an asthma attack gives hope to …
School 
3/10/15 
★ 

Keck School of Medicine of USC Scientists Open Door for Asthma Cure
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile